Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent form voluntarily.~* Male or female，age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the ICF.~* Expected life expectance ≥ 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.~* Confirmation either by histology unresectable hepatocellular carcinoma..~* BCLC stage C, and non-resectable BCLC stage B .~* No prior systemic therapy for HCC.~* Child-Pugh class A and B (≤7 points).~* At least one measurable lesion according to RECIST criteria.~* Adequate hematologic and end-organ function.~* For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent.~Exclusion Criteria:~* Prior treatment with anti-PD1, anti-PD-L1 or anti-CTLA-4 antibody therapy.~* Active ongoing infection requiring therapy.~* History of severe hypersensitivity reaction to another monoclonal antibody.~* Received any live attenuated vaccine within the last 30 days.~* Other malignancy requiring treatment in the prior 5 years with the exception of locally treated squamous or basal cell carcinoma.~* Pregnant, breast feeding, or planning to become pregnant.~* Active or prior documented autoimmune or inflammatory disease with some exceptions.~* Central nervous system metastases and/or carcinomatous meningitis.~* Medical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medication.~* Co-infection of HBV and HCV.~* Inadequately controlled arterial hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AK105 and anlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).